An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)

Respiration

Volumn 94, Issue 5, 2017, Pages 408-415

  Costabel, Ulrich ^a   Albera, Carlo ^b   Lancaster, Lisa H ^c   Lin, Chin Yu ^d   Hormel, Philip ^d   Hulter, Henry N ^d   Noble, Paul W ^e  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF TURIN   (Italy)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d GENENTECH INC   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Idiopathic pulmonary fibrosis; Long term safety; Pirfenidone

Indexed keywords

PIRFENIDONE; PLACEBO; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ACUTE RESPIRATORY FAILURE; AGED; ARTICLE; ATRIAL FIBRILLATION; BRONCHITIS; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RASH; RESPIRATORY FAILURE; RHINOPHARYNGITIS; SURVIVAL RATE; TREATMENT DURATION; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; PHASE 3 CLINICAL TRIAL;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PYRIDONES;

EID: 85029452570     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000479976     Document Type: Article

References (18)

1. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, Richeldi L, Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, Schunemann HJ; American Thoracic Society; European Respiratory Society; Japanese Respiratory Society; Latin American Thoracic Association: An Official ATS/ERS/ JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015; 192:e3-e19.
2. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group: A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
3. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
4. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan: Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829.
5. Loeh B, Drakopanagiotakis F, Bandelli GP, von der Beck D, Tello S, Cordani E, Rizza E, Barrocu L, Markart P, Seeger W, Guenther A, Albera C: Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2015; 191: 110-113.
6. Chaudhuri N, Duck A, Frank R, Holme J, Leonard C: Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir Med 2014; 108: 224-226.
7. Oltmanns U, Kahn N, Palmowski K, Trager A, Wenz H, Heussel CP, Schnabel PA, Puderbach M, Wiebel M, Ehlers-Tenenbaum S, Warth A, Herth FJ, Kreuter M: Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration 2014; 88: 199-207.
8. Wijsenbeek MS, Grutters JC, Wuyts WA: Early experience of pirfenidone in daily clinical practice in Belgium and the Netherlands: a retrospective cohort analysis. Adv Ther 2015; 32: 691-704.
9. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr: Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 459-466.
10. Karimi-Shah BA, Chowdhury BA: Forced vital capacity in idiopathic pulmonary fibrosis-FDA review of pirfenidone and nintedanib. N Engl J Med 2015; 372: 1189-1191.
11. Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE Jr: Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J 2016; 47: 243-253.
12. Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE Jr, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW: Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir Res 2016; 3: e000105.
13. Valeyre D, Albera C, Bradford WZ, Costabel U, King TE Jr, Leff JA, Noble PW, Sahn SA, du Bois RM: Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 2014; 19: 740-747.
14. Cottin V, Maher T: Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev 2015; 24: 58-64.
15. Costabel U, Bendstrup E, Cottin V, Dewint P, Egan JJ, Ferguson J, Groves R, Hellstrom PM, Kreuter M, Maher TM, Molina-Molina M, Nordlind K, Sarafidis A, Vancheri C: Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drugrelated adverse events. Adv Ther 2014; 31: 375-391.
16. Costabel U, Albera C, Bradford WZ, Hormel P, King TE Jr, Noble PW, Sahn SA, Valeyre D, du Bois RM: Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 198-205.
17. Esbriet (pirfenidone) capsules, for oral use (package insert). South San Francisco, Genentech, January 2017.
18. Duck A, Pigram L, Errhalt P, Ahmed D, Chaudhuri N: IPF Care: a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in Europe. Adv Ther 2015; 32: 87-107.